Drug Profile
Research programme: oral influenza therapeutics - TSRL
Alternative Names: TSR-026; TSR-462Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator TSRL
- Class Guanidines; Pyrans; Sialic acids
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Influenza virus infections
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (PO)
- 26 Jun 2014 Preclinical development is ongoing in the US
- 26 Jun 2014 Oral influenza therapeutics - TSRL is available for licensing (www.tsrlinc.com)